Trust Size
$524M
Peak Price
$896.94
Current Price
$72.14
Return
+621.4%
Price Journey
What Happened
GeneDx is a leading genomic diagnostics company and the most widely used provider of whole exome and whole genome sequencing for rare and undiagnosed genetic conditions in children.
GeneDx's public market journey began when Sema4 went public in July 2021 through a SPAC merger with CM Life Sciences (backed by Casdin Capital and Corvex Management). Sema4 then acquired GeneDx from BioReference Laboratories in 2022 and subsequently rebranded the entire company as GeneDx (ticker WGS). The company conducted a reverse stock split after the stock plummeted, but has since staged a remarkable comeback, with shares surging on strong demand for genetic testing and improving financials.
Timeline
2020-08-24
S-1 Registration Filed
2022-03-31
Merger Proxy Filed (DEFM14A)
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1818331
Total SEC Filings
732
State of Incorporation
DE
Last Filing Date
2026-03-17
Business Location
New York, NY
Trust/Asset Size
$524M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for GeneDx Holdings